RxDoctor Payments Data

Mark Krzyston, MD

Cardiovascular Disease · Orangeburg, SCNPI 1508923194

Payments from drug & device makers

$3,794in general payments, 2019–2025

Across 253 payments — averaging $15.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$483
  • Johnson & Johnson$478
  • Novartis$462
  • Pfizer$397
  • Merck$267
  • AstraZeneca$198
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$3,76099%
  • Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,794 in reported general payments places this provider in the 45th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$135,356
Medicare patients
1,087
Services billed
3,377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban590$433,902
EntrestoSacubitril/Valsartan301$233,673
JardianceEmpagliflozin134$83,169
XareltoRivaroxaban126$77,297
FarxigaDapagliflozin Propanediol72$50,613
MultaqDronedarone Hcl12$9,708
Metoprolol Succinate426$5,628
Rosuvastatin Calcium286$5,387
Losartan Potassium278$3,990
Digoxin175$3,202
Olmesartan Medoxomil82$3,198
Amlodipine Besylate527$3,186
Ezetimibe124$3,142
Nebivolol Hcl34$3,080
Atorvastatin Calcium268$2,757

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$397$433,902590 claims
NovartisEntresto$462$233,673301 claims
Boehringer IngelheimJardiance$161$83,169134 claims
Johnson & JohnsonXarelto$478$77,297126 claims
AstraZenecaFarxiga$198$50,61372 claims
Sanofi-aventis U.S. LLCMultaq$81$9,70812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Orangeburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →